- Researchers will evaluate whether the cannabinoid
therapeutic candidate can address joint pain resulting from cancer
treatment using aromatase inhibitors
- This side effect has caused many breast cancer patients to
discontinue treatment
LOS ANGELES and MONTEREY, Calif., Sept. 12,
2024 /PRNewswire/ -- City of Hope®, one of
the largest cancer research and treatment organizations in
the United States, and
Biopharmaceutical Research Company (BRC), a specialty
pharmaceutical company developing proprietary cannabinoid
therapeutics, announced today that the first patient has received
BRC-001, an experimental supportive care therapy for breast cancer
patients. City of Hope researchers are evaluating whether this
cannabinoid therapeutic candidate could address joint pain
(arthralgia) that is often a side effect of aromatase inhibitors, a
type of hormone therapy used to treat postmenopausal women with
breast cancer.
Aromatase inhibitors such as letrozole, anastrozole or
exemestane are prescribed as standard of care for postmenopausal
women with estrogen-receptor positive breast cancer to decrease
breast cancer recurrence and mortality. About half of patients who
take aromatase inhibitors experience joint pain, and many of these
patients report severe symptoms. A significant number of patients
discontinue cancer treatment due to this side effect. Currently,
there is no approved treatment for aromatase inhibitor-induced
arthralgia (AIIA). Patients often use over-the-counter,
anti-inflammatory medications and other treatment options with
limited efficacy for short-term pain management.
"Cannabis-derived therapeutics are one of the most promising
treatments to address underserved pain conditions. BRC has
developed a proprietary therapy with unique properties to address
joint pain in breast cancer patients taking aromatase inhibitors.
We look forward to providing a therapy for these patients that
allows them to complete a full course of treatment," said
George Hodgin, CEO and founder of
BRC, the industry leader in federally compliant cannabinoid
therapeutics development.
"This research to alleviate or eliminate side effects, such
as joint pain, is part of City of Hope's commitment to provide
compassionate, individualized care," said Lisa Yee, M.D., City of Hope professor of breast
surgery and lead investigator of the trial. "We hope this
work will yield innovative, FDA-approved therapies to help
patients complete their lifesaving treatments."
The clinical trial entitled "High Cannabidiol (CBD) Standardized
Extract for Aromatase Inhibitor-Induced Arthralgia – A randomized
controlled double blind clinical trial" is a randomized,
placebo-controlled study at City of Hope's Los Angeles cancer center. It is designed to
assess the safety, tolerability and efficacy of a botanically
derived proprietary formulation developed by BRC (BRC-001) when
taken orally to address the symptoms of AIIA.
Yuman Fong, M.D., Sangiacomo Family Chair in Surgical Oncology
at City of Hope, added, "Cannabis-derived medicines hold promise in
alleviating symptoms of cancer and cancer therapy. They are
potentially alternatives to opiates for pain relief, and
alternatives to benzodiazepines for relief of anxiety and insomnia.
We look forward to working with BRC in conducting trials to bring
these medicines forward to help patients suffering from
cancer."
Forward-Looking Statements
This news release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 that involve risks, uncertainties and assumptions,
including without limitation statements about the development, use,
benefits and effects of Biopharmaceutical Research Company's (BRC)
therapeutic product candidate and related technology, future plans
for the BRC's business and growth, expected plans with respect to
clinical trials, including the number of patients enrolled and
timing of patient enrollment. In some cases, you can identify
forward-looking statements by terms such as "may," "will,"
"should," "expect," "design," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplates," "believes,"
"estimates," "predicts," "potential" or "continue" or the negative
of these terms or other similar expressions. Such statements and
other statements in this press release that are not descriptions of
historical facts are forward-looking statements that are based on
management's current expectations and assumptions and are subject
to risks and uncertainties. If such risks or uncertainties
materialize or such assumptions prove incorrect, our business,
operating results, financial condition, and stock price could be
materially negatively affected. Actual results and the timing of
events could differ materially from those anticipated in these
forward-looking statements. The forward-looking statements made
herein speak only as of the date of this press release and, unless
otherwise required by law, BRC does not undertake any obligation to
publicly update such forward-looking statements to reflect
subsequent events or circumstances.
About City of Hope
City of Hope's mission is to make
hope a reality for all touched by cancer and diabetes. Founded in
1913, City of Hope has grown into one of the largest and
most advanced cancer research and treatment organizations in the
U.S., and one of the leading research centers for diabetes and
other life-threatening illnesses. City of Hope research has been
the basis for numerous breakthrough cancer medicines, as well
as human synthetic insulin and monoclonal antibodies. With an
independent, National Cancer Institute-designated comprehensive
cancer center that is ranked top 5 in the nation for cancer care by
U.S. News & World Report at its core, City of Hope's uniquely
integrated model spans cancer care, research and development,
academics and training, and a broad philanthropy program that
powers its work. City of Hope's growing national system includes
its Los Angeles campus, a network
of clinical care locations across Southern California, a new cancer center in
Orange County, California, and
cancer treatment centers and outpatient facilities in the
Atlanta, Chicago and Phoenix areas. City of Hope's affiliated group
of organizations includes Translational Genomics Research
Institute and AccessHope™. For more information about
City of Hope, follow us
on Facebook, X, YouTube, Instagram and LinkedIn.
About Biopharmaceutical Research
Company
Biopharmaceutical Research Company (BRC) is a
specialty pharmaceutical company focused on developing proprietary
cannabinoid therapeutics to address high unmet medical needs. BRC's
therapeutics are polymodal and contain major and minor cannabinoids
at strictly defined and proprietary ratios. The company is
developing a pipeline of treatments addressing pain and
neurological and inflammatory conditions. BRC is registered with
the Drug Enforcement Administration and is based in Monterey, CA.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/city-of-hope-and-biopharmaceutical-research-company-announce-first-patient-has-received-brc-001-a-first-in-class-cannabinoid-therapeutic-in-a-clinical-trial-investigating-supportive-care-in-breast-cancer-302246818.html
SOURCE Biopharmaceutical Research Company